Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Targeting retinal vascular disease
February 2020
SHARING OPTIONS:

CAMBRIDGE, U.K.—Biotechnology company Exonate shared news last month of a strategic collaboration agreement with Janssen Pharmaceuticals Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, to develop an eye drop treatment for retinal vascular diseases such as wet age-related macular degeneration and diabetic macular edema using mRNA-targeted therapies. Exonate's pipeline includes small molecules that inhibit the production of pro-angiogenic vascular endothelial growth factor (VEGF) via selective inhibition of serine/threonine-protein kinase-mediated VEGF splicing.
 
Dr. Catherine Beech, CEO of Exonate, said: “I am absolutely delighted to enter this strategic collaboration with Janssen; we are looking forward to successfully developing a novel treatment for retinal neovascular diseases.”

Back



PAGE UTILITIES


CONTACT US
DDNEWS
1000 N West Street, Suite 1200,
Wilmington, Delaware, 19801
Ph: 888-781-0328 |  Fax: 705-528-0270
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.